These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 35634324)

  • 21. Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection.
    Monteil V; Dyczynski M; Lauschke VM; Kwon H; Wirnsberger G; Youhanna S; Zhang H; Slutsky AS; Hurtado Del Pozo C; Horn M; Montserrat N; Penninger JM; Mirazimi A
    EMBO Mol Med; 2021 Jan; 13(1):e13426. PubMed ID: 33179852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
    Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M
    mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis.
    Focosi D; Maggi F; McConnell S; Casadevall A
    Antiviral Res; 2022 Feb; 198():105247. PubMed ID: 35033572
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication.
    Bravo JPK; Dangerfield TL; Taylor DW; Johnson KA
    Mol Cell; 2021 Apr; 81(7):1548-1552.e4. PubMed ID: 33631104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical effectiveness.
    Mechineni A; Kassab H; Manickam R
    Expert Opin Drug Saf; 2021 Nov; 20(11):1299-1307. PubMed ID: 34338121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination Treatment With Remdesivir and Ivermectin Exerts Highly Synergistic and Potent Antiviral Activity Against Murine Coronavirus Infection.
    Tan YL; Tan KSW; Chu JJH; Chow VT
    Front Cell Infect Microbiol; 2021; 11():700502. PubMed ID: 34395311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymerase.
    Babadaei MMN; Hasan A; Vahdani Y; Bloukh SH; Sharifi M; Kachooei E; Haghighat S; Falahati M
    J Biomol Struct Dyn; 2021 Jul; 39(10):3771-3779. PubMed ID: 32397906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: A retrospective study.
    Kojima Y; Nakakubo S; Kamada K; Yamashita Y; Takei N; Nakamura J; Matsumoto M; Horii H; Sato K; Shima H; Suzuki M; Konno S
    J Med Virol; 2022 Dec; 94(12):5702-5712. PubMed ID: 35916111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Remdesivir overcomes the S861 roadblock in SARS-CoV-2 polymerase elongation complex.
    Wu J; Wang H; Liu Q; Li R; Gao Y; Fang X; Zhong Y; Wang M; Wang Q; Rao Z; Gong P
    Cell Rep; 2021 Oct; 37(4):109882. PubMed ID: 34653416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Revealing the Inhibition Mechanism of RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2 by Remdesivir and Nucleotide Analogues: A Molecular Dynamics Simulation Study.
    Wakchaure PD; Ghosh S; Ganguly B
    J Phys Chem B; 2020 Nov; 124(47):10641-10652. PubMed ID: 33190493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanistic insight on the remdesivir binding to RNA-Dependent RNA polymerase (RdRp) of SARS-cov-2.
    Arba M; Wahyudi ST; Brunt DJ; Paradis N; Wu C
    Comput Biol Med; 2021 Feb; 129():104156. PubMed ID: 33260103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir.
    Yin W; Mao C; Luan X; Shen DD; Shen Q; Su H; Wang X; Zhou F; Zhao W; Gao M; Chang S; Xie YC; Tian G; Jiang HW; Tao SC; Shen J; Jiang Y; Jiang H; Xu Y; Zhang S; Zhang Y; Xu HE
    Science; 2020 Jun; 368(6498):1499-1504. PubMed ID: 32358203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Remdesivir: A beacon of hope from Ebola virus disease to COVID-19.
    Nili A; Farbod A; Neishabouri A; Mozafarihashjin M; Tavakolpour S; Mahmoudi H
    Rev Med Virol; 2020 Nov; 30(6):1-13. PubMed ID: 33210457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay.
    Jang WD; Jeon S; Kim S; Lee SY
    Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34234012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of Antivirals in SARS-CoV-2 Infection. Critical Review of the Role of Remdesivir.
    Moreno S; Alcázar B; Dueñas C; González Del Castillo J; Olalla J; Antela A
    Drug Des Devel Ther; 2022; 16():827-841. PubMed ID: 35370401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Piece of the puzzle: Remdesivir disassembles the multimeric SARS-CoV-2 RNA-dependent RNA polymerase complex.
    Olotu FA; Omolabi KF; Soliman MES
    Cell Biochem Biophys; 2021 Jun; 79(2):175-187. PubMed ID: 33792836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir.
    Camprubí D; Gaya A; Marcos MA; Martí-Soler H; Soriano A; Mosquera MDM; Oliver A; Santos M; Muñoz J; García-Vidal C
    Int J Infect Dis; 2021 Mar; 104():379-381. PubMed ID: 33359065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association and pharmacological synergism of the triple drug therapy baricitinib/remdesivir/rhACE2 for the management of COVID-19 infection.
    Vitiello A; Ferrara F
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Jan; 395(1):99-104. PubMed ID: 34669002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019.
    Martinot M; Jary A; Fafi-Kremer S; Leducq V; Delagreverie H; Garnier M; Pacanowski J; Mékinian A; Pirenne F; Tiberghien P; Calvez V; Humbrecht C; Marcelin AG; Lacombe K
    Clin Infect Dis; 2021 Oct; 73(7):e1762-e1765. PubMed ID: 32986807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment.
    Jung LS; Gund TM; Narayan M
    Protein J; 2020 Dec; 39(6):619-630. PubMed ID: 33185784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.